For example, restoration of BRCA1/BRCA2 activity due to reversion mutations, promoter demethylation [231,232], or the amplification of the mutant BRCA2 allele [233] have all been associated with cancer resistance to PARPi. This evidence concerns the gene BRCA2 and cancer.